Genetic Technologies Ltd (GENE) 0.37 $GENE
Genetic Technologies Announces Quarterly BREVAGen(TM) Results
Marketwire - Mon Oct 06, 4:42AM CDT
Molecular diagnostics (MDx) company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"
reported 942 BREVAGen(TM) test samples received in the September Quarter 2014, ahead of the release of the second generation breast cancer risk assessment test, BREVAGenplus(R), in October 2014.
GENE: 0.37 (-0.01)
Genetic Technologies Launches BREVAGenplus(R) Breast Cancer Risk Assessment Test
Marketwire - Wed Oct 01, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" ) is pleased to announce the US launch of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the Company's first generation product, BREVAGen(TM). BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman's five-year and lifetime risk of developing the disease. It is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. The test is directed towards Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
GENE: 0.37 (-0.01)
Genetic Technologies Announces Appointment of Independent Non-Executive Directors
Marketwire - Wed Sep 24, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" is pleased to advise that Mr. David Carter and Dr. Lindsay Wakefield have today been appointed Non-Executive Directors of the Company on "casual appointment", in that the new appointees will then be required to submit themselves for re-election at the upcoming AGM, as per article 19.4 of the Company's Constitution. The initial Director's interest notice - Appendix 3X, on behalf of Mr. Carter and Dr. Wakefield are attached.
GENE: 0.37 (-0.01)
Genetic Technologies Announces Divestment of Australian Based Heritage Business
Marketwire - Mon Sep 22, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" ) is pleased to announce that it has signed a binding contract of sale for its heritage Australian Genetics business ("Australian Genetics" to Specialist Diagnostics Services Ltd ("SDS" , the wholly owned pathology subsidiary of Primary Health Care Ltd. The Australian Genetics business provides diagnostic and sequencing services encompassing Australia-only medical, forensic, paternity and animal genomic testing. Under the terms of sale, SDS will acquire the Australian Genetics business for $2,000,000 in cash. Assuming all conditions are met, settlement of the transaction is expected to occur within the next month.
GENE: 0.37 (-0.01)
Transformational Restructuring Plans to Support Molecular Diagnostics Focus and Finalisation of Financing
Marketwire - Mon Sep 15, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" is pleased to announce plans for the restructure and realignment of group activities. These changes will enable the Company to focus its strategy on the US molecular diagnostics ("MDx" market and commercialisation of the Company's lead breast cancer risk test BREVAGen(TM). The restructure and realignment of group activities follows a recent review of operations by the Company aimed at supporting the Company's US MDx strategy. The core plans approved by the Board include:
GENE: 0.37 (-0.01)
Genetic Technologies Announces Further Patent Success in USA
Marketwire - Tue Aug 26, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that the United States District Court for the Middle District of North Carolina last week issued an Order denying a motion brought by GlaxoSmithKline, LLC (GSK) to dismiss the patent infringement law suit brought against it by GTG.
GENE: 0.37 (-0.01)
Why Genetic Technologies (GENE) Stock Is Spiking Today
at The Street - Mon Jul 07, 1:31PM CDT
Gene Technologies (GENE) shares are climbing after reporting a rise in sales of its cheek swab breast caner test, BREVAGen.
GENE: 0.37 (-0.01)
Genetic Technologies Provides BREVAGen(TM) Revenue Update for Quarter Ending June 30, 2014
Marketwire - Mon Jul 07, 4:30AM CDT
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that the number of BREVAGen(TM) test samples received during the quarter ended June 30, 2014 returned to levels achieved in late CY13. Total patient samples received during the quarter were 1,096, representing 37% growth over the March 2014 quarter (800 samples).
GENE: 0.37 (-0.01)
Genetic Technologies Announces Update on Intellectual Property
Marketwire - Wed Feb 12, 11:26AM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that it received a further ExParte Re-Examination Certificate from the United States Patent and Trademark Office ("USPTO" , dated February 10, 2014 (the "Certificate" . The Certificate follows the third request for ex parte re-examination of claims 1-15, 17,18, 26-29 and 32 of the Company's U.S. Patent No. 5,612,179 (the '179 patent) by Merial L.L.C. of Duluth, Georgia, as announced by the Company on September 30, 2013.
GENE: 0.37 (-0.01)
Genetic Technologies Announces Share Reduction Schedule With Major Shareholder
Marketwire - Wed Dec 18, 12:58PM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that entities associated with the Company's founder and largest shareholder, Dr. Mervyn Jacobson (collectively, the "Jacobson Entities" , have entered into several transactions which will result in the disposal of 105,937,500 shares in the Company. As a result, Dr. Jacobson's beneficial interest in the issued capital of the Company will be reduced from 23.83% to 6.15%.
GENE: 0.37 (-0.01), AUQ: 3.30 (-0.02)
Genetic Technologies Announces Quarterly BREVAGen(TM) Results
Marketwire - Mon Oct 06, 4:42AM CDT
Molecular diagnostics (MDx) company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"
reported 942 BREVAGen(TM) test samples received in the September Quarter 2014, ahead of the release of the second generation breast cancer risk assessment test, BREVAGenplus(R), in October 2014. GENE: 0.37 (-0.01)
Genetic Technologies Launches BREVAGenplus(R) Breast Cancer Risk Assessment Test
Marketwire - Wed Oct 01, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" ) is pleased to announce the US launch of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the Company's first generation product, BREVAGen(TM). BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman's five-year and lifetime risk of developing the disease. It is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. The test is directed towards Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
GENE: 0.37 (-0.01)
Genetic Technologies Announces Appointment of Independent Non-Executive Directors
Marketwire - Wed Sep 24, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"
is pleased to advise that Mr. David Carter and Dr. Lindsay Wakefield have today been appointed Non-Executive Directors of the Company on "casual appointment", in that the new appointees will then be required to submit themselves for re-election at the upcoming AGM, as per article 19.4 of the Company's Constitution. The initial Director's interest notice - Appendix 3X, on behalf of Mr. Carter and Dr. Wakefield are attached. GENE: 0.37 (-0.01)
Genetic Technologies Announces Divestment of Australian Based Heritage Business
Marketwire - Mon Sep 22, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" ) is pleased to announce that it has signed a binding contract of sale for its heritage Australian Genetics business ("Australian Genetics"
to Specialist Diagnostics Services Ltd ("SDS" , the wholly owned pathology subsidiary of Primary Health Care Ltd. The Australian Genetics business provides diagnostic and sequencing services encompassing Australia-only medical, forensic, paternity and animal genomic testing. Under the terms of sale, SDS will acquire the Australian Genetics business for $2,000,000 in cash. Assuming all conditions are met, settlement of the transaction is expected to occur within the next month. GENE: 0.37 (-0.01)
Transformational Restructuring Plans to Support Molecular Diagnostics Focus and Finalisation of Financing
Marketwire - Mon Sep 15, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"
is pleased to announce plans for the restructure and realignment of group activities. These changes will enable the Company to focus its strategy on the US molecular diagnostics ("MDx" market and commercialisation of the Company's lead breast cancer risk test BREVAGen(TM). The restructure and realignment of group activities follows a recent review of operations by the Company aimed at supporting the Company's US MDx strategy. The core plans approved by the Board include: GENE: 0.37 (-0.01)
Genetic Technologies Announces Further Patent Success in USA
Marketwire - Tue Aug 26, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that the United States District Court for the Middle District of North Carolina last week issued an Order denying a motion brought by GlaxoSmithKline, LLC (GSK) to dismiss the patent infringement law suit brought against it by GTG.
GENE: 0.37 (-0.01)
Why Genetic Technologies (GENE) Stock Is Spiking Today
at The Street - Mon Jul 07, 1:31PM CDT
Gene Technologies (GENE) shares are climbing after reporting a rise in sales of its cheek swab breast caner test, BREVAGen.
GENE: 0.37 (-0.01)
Genetic Technologies Provides BREVAGen(TM) Revenue Update for Quarter Ending June 30, 2014
Marketwire - Mon Jul 07, 4:30AM CDT
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that the number of BREVAGen(TM) test samples received during the quarter ended June 30, 2014 returned to levels achieved in late CY13. Total patient samples received during the quarter were 1,096, representing 37% growth over the March 2014 quarter (800 samples).
GENE: 0.37 (-0.01)
Genetic Technologies Announces Update on Intellectual Property
Marketwire - Wed Feb 12, 11:26AM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that it received a further ExParte Re-Examination Certificate from the United States Patent and Trademark Office ("USPTO"
, dated February 10, 2014 (the "Certificate" . The Certificate follows the third request for ex parte re-examination of claims 1-15, 17,18, 26-29 and 32 of the Company's U.S. Patent No. 5,612,179 (the '179 patent) by Merial L.L.C. of Duluth, Georgia, as announced by the Company on September 30, 2013. GENE: 0.37 (-0.01)
Genetic Technologies Announces Share Reduction Schedule With Major Shareholder
Marketwire - Wed Dec 18, 12:58PM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that entities associated with the Company's founder and largest shareholder, Dr. Mervyn Jacobson (collectively, the "Jacobson Entities"
, have entered into several transactions which will result in the disposal of 105,937,500 shares in the Company. As a result, Dr. Jacobson's beneficial interest in the issued capital of the Company will be reduced from 23.83% to 6.15%. GENE: 0.37 (-0.01), AUQ: 3.30 (-0.02)
